Is tucatinib/tucatinib already on the market in the country?

Tucatinib/Tucatinib (Tucatinib), as a highly selective HER2-targeting drug, has received widespread attention in the field of international cancer treatment in recent years. The drug was developed by the American company Seagen and is mainly used to treat HER2-positive breast cancer, especially those patients who have received multiple lines of treatment but whose disease still progresses. It blocks the growth and spread of tumor cells by precisely inhibiting the HER2 signaling pathway. Compared with traditional chemotherapy or broad-spectrum targeted drugs, tucatinib has shown unique advantages in controlling disease progression and has been approved for marketing in the United States, Canada, Europe and other regions. However, as of now, the original drug of tucatinib has not been officially marketed in mainland China.

At present, there are no officially approved tucatinib products in China that have entered the drug registration catalog of the National Medical Products Administration (NMPA), which means that patients are temporarily unable to purchase the drug in hospital pharmacies or domestic pharmaceutical company channels. If some patients have clinical needs, they usually obtain them through regular overseas pharmacies or international drug import channels. With the continuous development of global multi-center clinical studies, Chinese scientific research institutions have participated in the clinical verification of a number of HER2-targeted drugs, so the possibility of tucatinib entering the Chinese market in the future is gradually increasing.

From a policy perspective, China has accelerated the review and approval of innovative drugs in recent years, especially for targeted tumor drugs. If they have sufficient safety and efficacy data to support them overseas, the approval process is expected to be accelerated. It is generally believed in the industry that with the growing demand for precision treatment of HER2-positive breast cancer, tucatinib is expected to become a new generation of HER2 pathway inhibitors after trastuzumab and pertuzumab, further enriching clinical treatment options.

Reference materials:https://www.tukysa.com/